2
|
· |
the initiation, timing, progress and results of our current and future clinical trials of etripamil, including our Phase 3 clinical trials of etripamil for the treatment of PSVT, and of our research and development programs; |
|
· |
our plans to develop and commercialize etripamil and any future product candidates; |
|
· |
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
|
· |
our ability to successfully acquire or in-license additional product candidates on reasonable terms; |
|
· |
our ability to establish collaborations or obtain additional funding; |
|
· |
our ability to obtain regulatory approval of our current and future product candidates; |
|
· |
our expectations regarding the potential market size and the rate and degree of market acceptance of etripamil and any future product candidates; |
|
· |
our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources; |
|
· |
the implementation of our business model and strategic plans for our business, etripamil and any future product candidates; |
|
· |
our intellectual property position and the duration of our patent rights; |
3
|
· |
developments or disputes concerning our intellectual property or other proprietary rights; |
|
· |
our expectations regarding government and third-party payor coverage and reimbursement; |
|
· |
our ability to compete in the markets we serve; |
|
· |
the impact of government laws and regulations; |
|
· |
developments relating to our competitors and our industry; and |
|
· |
the factors that may impact our financial results. |